Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 2
Submit an article Journal homepage
2,758
Views
46
CrossRef citations to date
0
Altmetric
Original Research

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Hansol LeeMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaORCID Iconhttp://orcid.org/0000-0002-6270-1203View further author information
ORCID Icon,
Camelia QuekMelanoma Institute Australia, The University of Sydney, Sydney, NSW, AustraliaView further author information
,
Ines SilvaMelanoma Institute Australia, The University of Sydney, Sydney, NSW, AustraliaView further author information
,
Annie TaskerMelanoma Institute Australia, The University of Sydney, Sydney, NSW, AustraliaView further author information
,
Marcel BattenMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaView further author information
,
Helen RizosFaculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, AustraliaView further author information
,
Su Yin LimFaculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, AustraliaView further author information
,
Tuba Nur GideMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaView further author information
,
Ping ShangMelanoma Institute Australia, The University of Sydney, Sydney, NSW, AustraliaView further author information
,
Grace H. AttrillMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaView further author information
,
Jason MadoreMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaView further author information
,
Jarem EdwardsMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaView further author information
,
Matteo S. CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, NSW, AustraliaView further author information
,
Alexander GuminskiMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, AustraliaView further author information
,
Robyn P.M. SawMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, AustraliaView further author information
,
John F. ThompsonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, AustraliaView further author information
,
Peter M. FergusonMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, AustraliaView further author information
,
Umaimainthan PalendiraDiscipline of Infectious Diseases and Immunology, Sydney Medical School, The University of Sydney, Sydney, NSW, AustraliaView further author information
,
Alexander M. MenziesMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, AustraliaView further author information
,
Georgina V. LongMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, AustraliaORCID Iconhttp://orcid.org/0000-0001-8894-3545View further author information
ORCID Icon,
Richard A. ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, Australia;Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, AustraliaView further author information
&
James S. WilmottMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia;The University of Sydney Central Clinical School, Sydney, NSW, AustraliaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6750-5244View further author information
ORCID Icon show all
Article: e1537581 | Received 22 Mar 2018, Accepted 13 Oct 2018, Published online: 31 Oct 2018

References

  • Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.
  • Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206. doi:10.1200/JCO.2009.23.4799.
  • Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356. doi:10.1056/NEJMoa1709684.
  • Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030. doi:10.1200/JCO.2013.53.0105.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Jj G, Cl C, Cd L, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030.
  • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37. doi:10.1126/scitranslmed.3003689.
  • Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723. doi:10.1016/j.cell.2017.01.017.
  • Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. 2014;19:67–75.
  • Pallmer K, Oxenius A. Recognition and regulation of T cells by NK cells. Frontiers in Immunology. 2016;7:251.
  • Battaglia A, Ferrandina G, Buzzonetti A, Malinconico P, Legge F, Salutari V, Scambia G, Fattorossi A. Lymphocyte populations in human lymph nodes. Alterations in CD4 + CD25 + T regulatory cell phenotype and T-cell receptor Vbeta repertoire. Immunology. 2003;110:304–312.
  • Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C, van Diest P. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862. doi:10.1371/journal.pone.0051862.
  • Rinfret A, Anderson SK. IL-2 regulates the expression of the NK-TR gene via an alternate RNA splicing mechanism. Mol Immunol. 1993;30:1307–1313.
  • Sedelies KA, Sayers TJ, Edwards KM, Chen W, Pellicci DG, Godfrey DI, Trapani JA. Discordant regulation of granzyme H and granzyme B expression in human lymphocytes. J Biol Chem. 2004;279:26581–26587. doi:10.1074/jbc.M312481200.
  • Fellows E, Gil-Parrado S, Jenne DE, Kurschus FC. Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood. 2007;110:544–552. doi:10.1182/blood-2006-10-051649.
  • Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934–49 e15. doi:10.1016/j.cell.2017.09.028.
  • Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239–252. doi:10.1038/nri3174.
  • Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30:1666–1676. doi:10.1038/modpathol.2017.89.
  • Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, et al. NK cells and CD8 + T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015;3:18. doi:10.1186/s40425-015-0063-3.
  • Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7:72961–72977. doi:10.18632/oncotarget.12150.
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026.
  • Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi:10.1186/s13059-014-0550-8.
  • Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi:10.1093/bioinformatics/btu638.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.